Mitotech Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Latest Deal Type
  • Corporate
  • Latest Deal Amount
  • $20M
Latest Deal Amount
  • Investors
  • 2

Mitotech General Information

Description

Operator of a biotechnology company intended to develop novel drugs for the treatment of predominantly age-related disorders. The company's offerings are mitochondria targeting cardiolipin peroxidation inhibitors developed in several drug formulations covering a variety of therapeutic areas with a focus on ophthalmology and neurodegenerative diseases, enabling doctors to pass through the mitochondrial membrane and concentrate inside the mitochondria.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 42, rue de la Vallee
  • Luxembourg, 2661
  • Luxembourg

Mitotech Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Mitotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Corporate 30-Aug-2019 $20M 000.00 Completed Generating Revenue
2. Corporate 28-Aug-2018 0000 000.00 Completed Clinical Trials - Phase 3
1. Early Stage VC 24-Feb-2010 $22.9M $22.9M Completed Clinical Trials - Phase 3
To view Mitotech’s complete valuation and funding history, request access »

Mitotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biotechnology company intended to develop novel drugs for the treatment of predominantly age-related disor
Biotechnology
Luxembourg, Luxembourg
000.00
000000000000 000.00

000000

equat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000 000000000
Malvern, PA
00 As of 0000
000.00
000000000 - 000.00

0000000

e cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cu
0000000000000
Summit, NJ
0000 As of 0000
000.00
00.00 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mitotech Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ocugen Corporation Malvern, PA 00 000.00 000000000 - 000.00
0000000 Formerly VC-backed Summit, NJ 0000 000.00 000000&0 000.00
00000000 000000000 Corporation Durham, NC 000 00000 00000000 00000
000000000(00000000 Formerly VC-backed New York, NY 000 00000 000000 - 000 00000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
You’re viewing 5 of 20 competitors. Get the full list »

Mitotech Executive Team (4)

Name Title Board Seat Contact Info
Natalia Perekhvatova Board Member, Chief Education Officer, Chief Financial Officer & Board Member
Anton Petrov Ph.D Chief Operating Officer
Maxim Skulachev Ph.D Chief Scientific Officer
Lawrence Friedhoff Ph.D Chief Clinical Officer
To view Mitotech’s complete executive team members history, request access »

Mitotech Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Essex Bio-technology Corporation Minority 000 0000 000000 0
Rusnano Venture Capital Minority 000 0000 000000 0
To view Mitotech’s complete investors history, request access »